{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:16:26Z","timestamp":1777464986919,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T00:00:00Z","timestamp":1415059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"University of Kansas General Research Fund","award":["2302324"],"award-info":[{"award-number":["2302324"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eflornithine (<jats:italic>\u03b1<\/jats:italic>\u2010difluoromethylornithine) has been used to treat second\u2010stage (or meningoencephalitic\u2010stage) human African trypanosomiasis and currently is under clinical development for cancer prevention. In this study, a new ultraperformance liquid chromatography\u2013tandem mass spectrometry (UPLC\u2010MS\/MS)\u2010based assay was developed and validated for the quantification of eflornithine in rat brain. To improve chromatographic retention and MS detection, eflornithine was derivatized with 6\u2010aminoquinolyl\u2010<jats:italic>N<\/jats:italic>\u2010hydroxysuccinimidyl carbamate for 5\u2009min at room temperature prior to injection. Derivatized eflornithine was separated on a reverse\u2010phase C<jats:sub>18<\/jats:sub> UPLC column with a 6\u2010min gradient; elution occurred at approximately 1.5\u2009min. Prior to derivatization, eflornithine was reproducibly extracted from rat brain homogenate by methanol protein precipitation (~70% recovery). Derivatized eflornithine was stable in the autosampler (6\u2009\u00b0C) for at least 24\u2009h. This new assay had acceptable intra\u2010 and interday accuracy and precision over a wide dynamic range (5000\u2010fold) and excellent sensitivity with a lower limit of quantification of 0.1\u2009\u00b5<jats:sc>m<\/jats:sc> (18\u2009ng\/mL) using only 10\u2009\u03bcL of rat brain homogenate. The validated eflornithine assay was applied successfully to determine eflornithine distribution in different regions of rat brain in an <jats:italic>in situ<\/jats:italic> rat brain perfusion study. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.3374","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T02:01:33Z","timestamp":1415066493000},"page":"918-924","source":"Crossref","is-referenced-by-count":8,"title":["A simple and sensitive assay for eflornithine quantification in rat brain using pre\u2010column derivatization and UPLC\u2010MS\/MS detection"],"prefix":"10.1002","volume":"29","author":[{"given":"Sihyung","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy The University of Kansas  Lawrence Kansas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan\u2010Wei","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy The University of Kansas  Lawrence Kansas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Zhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy The University of Kansas  Lawrence Kansas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2008.00215.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-002-0766-5"},{"issue":"10","key":"e_1_2_7_4_1","first-page":"3850","article-title":"Bioavailability study of oral liquid and tablet forms of alpha\u2010difluoromethylornithine","volume":"6","author":"Carbone PP","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/432576"},{"issue":"16","key":"e_1_2_7_6_1","first-page":"4466","article-title":"Comparative antitumor properties in rodents of irreversible inhibitors of l\u2010ornithine decarboxylase, used as such or as prodrugs","volume":"49","author":"Claverie N","year":"1989","journal-title":"Cancer Research"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1993.1270"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600780208"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(89)90346-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)80114-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(94)00064-6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00438-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(96)00818-7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9673(95)00604-L"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1361"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.capr-12-0429"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(98)00086-7"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp100293m"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/1998053239"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.08.030"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.capr-08-0042"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61117-x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05706.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001007"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015943408386"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1221"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03548.x"},{"key":"e_1_2_7_28_1","unstructured":"US Food and Drug Administration.Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services FDA Center for Drug Evaluation and Research: Rockville MD 2013."}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.3374","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.3374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:43:40Z","timestamp":1760046220000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.3374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/bmc.3374"],"URL":"https:\/\/doi.org\/10.1002\/bmc.3374","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,4]]}}}